KR880007433A - 3-아릴옥시-3-치환된 프로판아민 - Google Patents

3-아릴옥시-3-치환된 프로판아민

Info

Publication number
KR880007433A
KR880007433A KR860014449A KR860014449A KR880007433A KR 880007433 A KR880007433 A KR 880007433A KR 860014449 A KR860014449 A KR 860014449A KR 860014449 A KR860014449 A KR 860014449A KR 880007433 A KR880007433 A KR 880007433A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
formula
methyl
thienyl
Prior art date
Application number
KR860014449A
Other languages
English (en)
Inventor
웨인 로버트 슨 데이비드
타이웨이 웡 데이비드
제이알. 요셉 헤르만 크루쉰스키
Original Assignee
메리 앤 터커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메리 앤 터커, 일라이 릴리 앤드 캄파니 filed Critical 메리 앤 터커
Publication of KR880007433A publication Critical patent/KR880007433A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Abstract

내용 없음.

Description

3-아릴옥시-3-치환된 프로판아민
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 다음 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 산부가염.
    상기 식에서, R1은 C6-C7사이클로알킬, 티에닐, 할로티에닐, (C1-C4알킬)티에닐, 푸라닐, 피리딜 또는 티아졸릴이고;
    R2및 R3은 각각 독립적으로 수소 또는 메틸이고; R4는 각각 독립적으로 할로, C1-C4알킬 또는 트리플루오로메틸이고; R1은 각각 독립적으로 할로, C1-C4알킬 또는 트리플루오로메틸이고; m은 0.1 또는 2이며; n은 0 또는 1이다.
  2. 제1항에 있어서, Ar이인 화합물
  3. 제1항 또는 2항에 있어서, R1이 티에닐인 화합물.
  4. 제1항 내지 3항중 어느 한 항에 있어서, R2및 R3중 하나는 수소이고 다른 하나는 메틸인 화합물.
  5. N-메틸-3-(1-나프탈렌닐옥시)-3-(2-티에닐)프로판아민, 또는 약제학적으로 허용되는 이의 산부가염.
  6. 제5항에 있어서, 화합물이(+)-입체이성체인 화합물.
  7. (+)-메틸-3-(1-나프탈레닐옥시)-3-(2-티에닐)프로판아민 말리에이트.
  8. 제l항 내지 7항중 어느 한 항에서 청구된 일반식(l)의 화합물, 또는 약제학적으로 허용되는 이의 산부가염을 하나이상의 약제학적으로 허용되는 이의 담체, 희석제 또는 부형제와 결합되게 포함하는 약제학적 제형.
  9. 포유류에 있어서 세로토닌 및 노르에피네프린의 흡수 억제에 사용되는 일반식(l)의 화합물, 또는 약제학적으로 허용되는 이의 염.
  10. (A)가 일반식의 화합물을 하이드록시 함유 화합물의 음이온을 생성시키기에 충분한 강염기의 존재하에 일반식 Rl, R2, R3및 Ar는 제1항에서 정의된 바와 같으며 X 및 Y중 하나는 수소이고 다른 하나는 좋은 이탈 그룹인 Y-Ar의 시약과 반응시키거나, (B) R2및 R3이 둘다 메틸인 일반식(I)의 화합물을 탈메틸화하여 R2및 R3중 하나가 수소이고 다른 하나가 메틸인 일반식(I)의 화합물을 생성시키고, (C) 상기 반응(A) 또는 (B)를 거친후 필요에 따라 염화시켜 약제학적으로 허용되는 산부가염을 형성시킴을 포함하여, 제1항 내지 제7항중 어느 하나에서 청구된 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR860014449A 1986-12-22 1986-12-18 3-아릴옥시-3-치환된 프로판아민 KR880007433A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94512286A 1986-12-22 1986-12-22
US06/945122 1986-12-22

Publications (1)

Publication Number Publication Date
KR880007433A true KR880007433A (ko) 1988-08-27

Family

ID=25482649

Family Applications (2)

Application Number Title Priority Date Filing Date
KR860014449A KR880007433A (ko) 1986-12-22 1986-12-18 3-아릴옥시-3-치환된 프로판아민
KR1019870014449A KR960003808B1 (ko) 1986-12-22 1987-12-18 3-아릴옥시-3-치환된 프로판아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019870014449A KR960003808B1 (ko) 1986-12-22 1987-12-18 3-아릴옥시-3-치환된 프로판아민, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (27)

Country Link
EP (1) EP0273658B1 (ko)
JP (1) JP2549681B2 (ko)
KR (2) KR880007433A (ko)
CN (1) CN1019113B (ko)
AR (1) AR243868A1 (ko)
AT (1) ATE57924T1 (ko)
AU (1) AU591007B2 (ko)
CA (1) CA1302421C (ko)
CY (2) CY1682A (ko)
DE (3) DE122005000002I1 (ko)
DK (1) DK174599B1 (ko)
EG (1) EG18230A (ko)
ES (1) ES2019949B3 (ko)
GR (1) GR3001207T3 (ko)
HK (1) HK69693A (ko)
HU (1) HU206309B (ko)
IE (1) IE873449L (ko)
IL (1) IL84863A (ko)
LU (1) LU91131I2 (ko)
MX (1) MX9845A (ko)
NL (1) NL300171I2 (ko)
NZ (1) NZ222980A (ko)
PH (1) PH26556A (ko)
PT (1) PT86389B (ko)
SG (1) SG114992G (ko)
SU (1) SU1598865A3 (ko)
ZA (1) ZA879472B (ko)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
CA2042346A1 (en) * 1990-05-17 1991-11-18 Michael Alexander Staszak Chiral synthesis of 1-aryl-3-aminopropan-1-ols
EP0571685A1 (en) * 1992-05-27 1993-12-01 Novo Nordisk A/S Aryloxyheteroarylpropylamines, their preparation and use
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
EP1411912A1 (en) * 2001-07-31 2004-04-28 PHARMACIA & UPJOHN COMPANY Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003078418A1 (fr) * 2002-03-19 2003-09-25 Mitsubishi Chemical Corporation Compose de 3-hydroxy-3-(2-thienyl)propionamide, procede de fabrication correspondant, et procede de fabrication d'un compose de 3-amino-1-(2-thienly)1-propanol a partir de ce dernier
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
EP1506965A4 (en) * 2002-05-20 2010-11-03 Mitsubishi Rayon Co PROPANOLAMINE DERIVATIVES, PROCESS FOR THE PREPARATION OF 3-N-METHYLAMINO-1- (2-THIENYL) -1-PROPANOLS AND PROCESS FOR THE PREPARATION OF PROPANOLAMINE DERIVATIVES
DE10235206A1 (de) * 2002-08-01 2004-02-19 Basf Ag Verfahren zur Herstellung von (S)-3-Methylmino-1-(thien-2-yl)propan-1-ol
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
DE10302595A1 (de) 2003-01-22 2004-07-29 Basf Ag 3-Methylamino-1-(2-thienyl)-1-proganon, seine Herstellung und Verwendung
DE10345772A1 (de) 2003-10-01 2005-04-21 Basf Ag Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol
DE102004004719A1 (de) 2004-01-29 2005-08-18 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
AU2005215906C1 (en) * 2004-02-19 2012-03-01 Lonza Ag Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols
DE102004022686A1 (de) 2004-05-05 2005-11-24 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US7973082B2 (en) 2004-08-26 2011-07-05 Neurosearch A/S Substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors
EP1730132A2 (en) * 2004-12-23 2006-12-13 Teva Pharmaceutical Industries Ltd Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
WO2006099459A1 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the preparation of optically active (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
DE102005044736A1 (de) 2005-09-19 2007-03-22 Basf Ag Neue Dehydrogenasen, deren Derivate und ein Verfahren zur Herstellung von optisch aktiven Alkanolen
WO2007038253A2 (en) * 2005-09-22 2007-04-05 Teva Pharmaceutical Industries Ltd. Dnt-maleate and methods of preparation thereof
ITMI20051970A1 (it) 2005-10-18 2007-04-19 Solmag S P A Processo per la preparazione di eteri misti derivanti dall'inaftolo e intermedi di forme cristalline definite di + e - duloxetina
BRPI0619184A2 (pt) * 2005-11-30 2011-09-13 Hoffmann La Roche 3-amino-2-arilpropil azaindóis e usos destes
WO2007067581A1 (en) 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphthol) thiophene, an impurity of duloxetine hydrochloride
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
DE102005062661A1 (de) 2005-12-23 2007-08-16 Basf Ag Verfahren zur Herstellung von optisch aktivem (1S)-3-Chlor-(-thien-2-yl)-propan-1-ol
DE102005062662A1 (de) 2005-12-23 2007-06-28 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
CZ299270B6 (cs) 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP1976844A4 (en) 2006-01-06 2010-11-03 Msn Lab Ltd IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE
WO2008077645A1 (en) 2006-12-22 2008-07-03 Synthon B.V. Process for making duloxetine and related compounds
US9233165B2 (en) * 2008-04-11 2016-01-12 Nektar Therapeutics Oligomer-aryloxy-substituted propanamine conjugates
EP2133072A1 (en) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
HU230480B1 (hu) * 2008-07-25 2016-07-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás N-metil-ariloxi-propánamin származékok előállítására
SI2329013T1 (sl) 2008-08-27 2016-03-31 Codexis, Inc. Polipeptidi ketoreduktaze za proizvodnjo 3-aril-3-hidroksipropanamina iz 3-aril-3-ketopropanamina
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
CZ304602B6 (cs) 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
EP2377525A1 (en) 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
WO2011128370A1 (en) 2010-04-13 2011-10-20 Krka, D.D., Novo Mesto Synthesis of duloxetine and/or pharmaceutically acceptable salts thereof
WO2012024397A2 (en) 2010-08-17 2012-02-23 Albany Molecular Research, Inc. 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2508519A1 (en) * 2011-04-07 2012-10-10 Bioindustria Laboratorio Italiano Medicinali S.p.A In forma abbreviata Bioindustria L.I.M. S.p.A. "Process for the preparation of duloxetine and its hydrochloride salt"
GR1007725B (el) 2011-10-17 2012-10-18 Φαρματεν Αβεε, Μεθοδος δια την παρασκευη υδροχλωρικης ντουλοξετινης υψηλης καθαροτητας
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
US9668975B2 (en) 2014-10-14 2017-06-06 PharmaDax Inc. Method of preparing drug agglomerate
CN105777706B (zh) 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法
JP6182183B2 (ja) * 2015-07-07 2017-08-16 東和薬品株式会社 デュロキセチン塩基及びデュロキセチン塩酸塩の製造方法
CN106349211B (zh) * 2016-08-26 2020-10-16 江苏恩华药业股份有限公司 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用
EP3339304A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
CN114206859A (zh) * 2019-05-16 2022-03-18 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2842555A (en) * 1954-07-27 1958-07-08 Burroughs Wellcome Co Method of preparing quaternary salts of amino carbinols
AT255400B (de) * 1965-03-22 1967-07-10 Chemie Linz Ag Verfahren zur Herstellung von neuen basischen Äthern
US3423510A (en) * 1966-08-31 1969-01-21 Geigy Chem Corp 3-(p-halophenyl) - 3 - (2'-pyridyl-n-methylpropylamine for the treatment of depression
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
FR2482956A1 (fr) * 1980-05-22 1981-11-27 Synthelabo Cyclohexylalkylamines, leurs procedes de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CY2005001I2 (el) 2009-11-04
CN1019113B (zh) 1992-11-18
DE122005000002I2 (de) 2006-08-24
DE3765919D1 (de) 1990-12-06
AU591007B2 (en) 1989-11-23
EG18230A (en) 1992-10-30
PH26556A (en) 1992-08-19
CY1682A (en) 1993-10-10
AR243868A1 (es) 1993-09-30
CA1302421C (en) 1992-06-02
PT86389B (pt) 1990-11-20
HU206309B (en) 1992-10-28
DK664887D0 (da) 1987-12-17
HUT47561A (en) 1989-03-28
SU1598865A3 (ru) 1990-10-07
LU91131I2 (fr) 2005-03-29
DK664887A (da) 1988-06-23
MX9845A (es) 1993-12-01
JP2549681B2 (ja) 1996-10-30
GR3001207T3 (en) 1992-07-30
CN87108175A (zh) 1988-07-06
ES2019949B3 (es) 1991-07-16
DE122005000002I1 (de) 2005-05-12
PT86389A (en) 1988-01-01
HK69693A (en) 1993-07-30
KR960003808B1 (ko) 1996-03-22
JPS63185946A (ja) 1988-08-01
IE873449L (en) 1988-06-22
EP0273658B1 (en) 1990-10-31
NL300171I2 (nl) 2005-06-01
DK174599B1 (da) 2003-07-14
EP0273658A1 (en) 1988-07-06
CY2005001I1 (el) 2009-11-04
SG114992G (en) 1993-01-29
AU8266087A (en) 1988-06-23
ZA879472B (en) 1989-08-30
ATE57924T1 (de) 1990-11-15
NZ222980A (en) 1989-11-28
IL84863A (en) 1992-03-29
IL84863A0 (en) 1988-06-30
NL300171I1 (nl) 2005-04-01

Similar Documents

Publication Publication Date Title
KR880007433A (ko) 3-아릴옥시-3-치환된 프로판아민
KR840004106A (ko) 4급 6,11-디하이드로-디벤조-[b,e]-티에핀-11-N-알킬-노르스코핀 에테르의 제조방법
KR860004060A (ko) 티에닐 축합 피라졸 유도체의 제조방법
FI810604L (fi) Foerfarande foer framstaellning av indanderivat
KR830009046A (ko) 아로일 이미다졸론의 제조방법
KR890014534A (ko) 혈당 감소제로서 티아졸리딘디온 유도체
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR900014396A (ko) 티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR910021394A (ko) 카르복실산 유도체
KR910016738A (ko) 질소함유고리계를 갖는 신규한 제약학적 화합물 및 조성물, 그들의 제조방법 및 그들을 사용한 트롬복산 신테타제 효소, 고혈압 및 부정맥의 억제 방법
KR900018113A (ko) 티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
ES8600240A1 (es) Metodo para preparar derivados de fenilindeno
KR890015995A (ko) 프로판아민 유도체
KR870006035A (ko) 신규 항균제 1-티에닐-4-옥소퀴놀린-3-카복실산 화합물의 제법
KR890003692A (ko) 1.2.5.6- 테트라히드로피리딘-3-카르복스알데히드의 옥심유도체, 이들의 제조방법, 약제로서의 이들의 용도 및 이들을 함유하는 조성물
KR880013929A (ko) 신규 5-메톡시 알킬 암노늄 테트라히드로푸란 및 테트라히드로티오펜
KR910015537A (ko) 신규 1-아릴술포닐-2-피페리디논 유도체, 이의 제조방법, 제조용 중간체, 의약품으로서의 용도 및 이 화합물을 함유하는 조성물
ATE1442T1 (de) Pharmazeutisches mittel, enthaltend all-e- oder 13-z-7,8-dehydro-retinsaeure und verfahren zu seiner herstellung.
KR850002478A (ko) 2-(n-피롤리디노)-3-이소부톡시-n-치환된 페닐-n-벤질-프로필아민의 제조방법
KR890012961A (ko) N-(저급알킬)-2-(3'-우레이도벤질)피롤리딘
KR910011815A (ko) 티아졸릴-5-카본아미드 유도체 및 그의 제조방법
KR920003970A (ko) 혈중 요산 함량의 강하 방법
KR850005435A (ko) 3-알콕시-2-(n-피롤리디노)-n-피리미디닐-또는 n-피라지닐 프로필아민의 제조방법
KR870001153A (ko) 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법